Press-release for stocks

Prices are updated after-hours

positive crawled time : 12:30

save search

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Published: 2024-04-10 (Crawled : 12:30) - prnewswire.com
MBRX | $4.28 -2.41% 6.9K

Health Technology

| -18.16% | O: 8.8% H: 3.87% C: -8.61%
presentation positive

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.21 -3.91% -6.48% 1.3K

Health Technology

| -25.34% | O: 2.36% H: 6.6% C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | $90.33 0.01% 0.01% 610

Health Services

| -2.51% | O: 2.12% H: 4.35% C: 2.25%
bladder positive cancer trial

C-Bond Systems Reports 2023 Highlights Including Record Revenue and Positive Net Income; Company to Host Conference Call on April 3rd
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
CBNT | $0.0042 7.69% 122.22% 0

Manufacturing

| -9.3% | O: -11.63% H: 7.89% C: 7.89%
conference company revenue positive

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
GNPX | $2.21 -3.91% -6.48% 1.3K

Health Technology

| -25.59% | O: -5.72% H: 7.14% C: 1.43%
oncoprex positive system preclinical therapy

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Published: 2024-03-28 (Crawled : 12:30) - globenewswire.com
NXL | $1.32 -10.81% -12.98% 30

| 69.23% | O: 8.99% H: 0.0% C: 0.0%
device positive technology results study

DEEP GREEN Completes Asset Sale of Georgia Subsidiary and Strengthens Company Cash Position
Published: 2024-03-25 (Crawled : 12:30) - globenewswire.com
DGWR | $0.0898 8.85% -98.05% 0

Manufacturing

| 150.14% | O: 38.16% H: 0.0% C: -25.81%
company

Summit Midstream Partners, LP Announces Sale of Utica Position for $625 Million
Published: 2024-03-22 (Crawled : 12:30) - prnewswire.com
SMLP | $28.23 0.18% 0.0% 0

Utilities

| 45.29% | O: 32.73% H: 5.66% C: 4.69%
MPLX | $39.99 0.83% 0.4% 8.5K

Industrial Services

| -1.67% | O: 0.02% H: 0.05% C: -0.27%
million

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Published: 2024-03-19 (Crawled : 12:30) - prnewswire.com
ICCM | $1.29 -0.77% -0.39% 10K

Manufacturing

| 6.61% | O: 2.07% H: 0.0% C: 0.0%
free company breast one positive cancer women topline medical alternative results

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Published: 2024-03-15 (Crawled : 12:30) - globenewswire.com
FBIO | $1.77 0.57% 1.68% 0

Health Technology

| 4.76% | O: 2.98% H: 15.03% C: 11.85%
ATXI | $0.1351 2.74% 3.38% 680

Health Technology

| -15.16% | O: -0.26% H: 13.2% C: 1.88%
nasdaq positive therapeutics

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.3754 -1.11% -2.58% 2M

n/a

| -9.62% | O: 7.14% H: 5.53% C: -4.67%
cyb003 fda positive meeting program design

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.34 -8.59% -9.17% 0

Health Technology

| 69.57% | O: 68.84% H: 62.66% C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $25.42 -1.05% 0.08% 110K

Health Technology

| -10.4% | O: -0.21% H: 0.11% C: -1.06%
adcetris positive trial

Proof Positive & Members of its Nationwide Autism Wellbeing Alliance Celebrate Global Commitment to the Autism Community on International Day of Happiness
Published: 2024-03-07 (Crawled : 12:30) - prnewswire.com
FNCTF | News | $11.0354 -0.83% -20.84% 34K

Communications

| -3.03% | O: 0.79% H: 0.78% C: 0.78%
day positive international global nationwide

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-23 (Crawled : 12:30) - prnewswire.com
ATNM | $7.25 -6.33% 8.69% 280K

Health Technology

| 14.84% | O: 4.45% H: 1.85% C: -2.56%
tp53 astct positive leukemia trial therapy

Agrify Receives Positive Nasdaq Listing Determination
Published: 2024-01-31 (Crawled : 12:30) - globenewswire.com
AGFY | News | $0.365 22.52% 17.8% 190K